BostonGene, University of Miami Ink Precision Oncology Collaboration in High-Grade B-Cell Lymphoma
BostonGene will use its next-generation sequencing technologies to analyze tumor samples collected at Sylvester and help guide treatment selection accordingly.
Mustang Bio Reprioritizes Pipeline, Sells Manufacturing Facility to Focus on Lead Assets
The company said it is nixing several pipeline programs and selling a manufacturing plant to uBriGene in order to focus on a CD20 CAR T-cell therapy and other nearer term opportunities.
UMiami Researchers to Study Cell Therapy Response in Lymphoma Using WGS, Single-Cell RNA-seq
The team has received a $1.5 million US Department of Defense grant to help launch its project on diffuse B-cell lymphoma resistance to CAR T-cell therapy.
Janssen, Cellular Biomedicine Group Sign Deal to Develop CAR T-Cell Therapies
The deal gives Janssen exclusive worldwide rights to CBMG's CD20-directed autologous CAR T-cell therapies, except in greater China.
Bristol Myers Squibb's Breyanzi Nets Second-Line Lymphoma Approval in Europe
The European Commission approved the autologous CAR T-cell therapy for relapsed lymphoma patients following first-line chemo-immunotherapy.